ArticleVaccines2021
Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Transcriptional signatures of rapid protection from Sudan virus infection by a single dose of a vesicular stomatitis virus-based vaccine.PLoS pathogens · 2026Article
- Article
- Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.EBioMedicine · 2025Article
- Human genetics of responses to vaccines.Clinical and experimental immunology · 2025Review
- Transcriptomic analysis after SARS-CoV-2 mRNA vaccination reveals a specific gene signature in low-responder hemodialysis patients.Frontiers in immunology · 2025Article
- Long non-coding RNAs in response to Ebola virus vaccine-induced immunity.Frontiers in immunology · 2025Article
- Deciphering Immune Responses to Immunization via Transcriptional Analysis: A Narrative Review of the Current Evidence towards Personalized Vaccination Strategies.International journal of molecular sciences · 2024Review
- Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP.iScience · 2023Article
- A Recombinant Vesicular Stomatitis Virus-Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection.The Journal of infectious diseases · 2023Article
- STAGEs: A web-based tool that integrates data visualization and pathway enrichment analysis for gene expression studies.Scientific reports · 2023Article
- Refined innate plasma signature after rVSVΔG-ZEBOV-GP immunization is shared among adult cohorts in Europe and North America.Frontiers in immunology · 2023Article
- A Bivalent Bacterium-like Particles-Based Vaccine Induced Potent Immune Responses against the Sudan Virus and Ebola Virus in Mice.Transboundary and emerging diseases · 2023Article
- Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccine.NPJ vaccines · 2022Article
- Article
- Immune Memory After Respiratory Infection WithFrontiers in cellular and infection microbiology · 2022Article
- Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity.Current opinion in virology · 2021Review
- Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 4 countries.
Funding
Abstract
Ebolavirus Disease (EVD) is a severe haemorrhagic fever that occurs in epidemic outbreaks, with a high fatality rate and no specific therapies available. rVSVΔG-ZEBOV-GP (Ervebo
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.